S&P 500   3,899.95 (+2.33%)
DOW   31,591.58 (+2.13%)
QQQ   322.20 (+2.57%)
AAPL   126.10 (+3.99%)
MSFT   237.00 (+1.99%)
FB   260.76 (+1.22%)
GOOGL   2,061.59 (+1.96%)
TSLA   714.67 (+5.80%)
AMZN   3,123.30 (+0.98%)
NVDA   549.87 (+0.24%)
BABA   240.47 (+1.14%)
CGC   34.90 (+6.56%)
GE   13.28 (+5.90%)
MU   95.64 (+4.49%)
NIO   50.27 (+9.81%)
AMD   85.87 (+1.61%)
T   28.22 (+1.18%)
F   12.07 (+3.16%)
ACB   11.30 (+7.41%)
DIS   195.05 (+3.18%)
BA   224.76 (+6.01%)
NFLX   549.87 (+2.05%)
BAC   35.67 (+2.77%)
S&P 500   3,899.95 (+2.33%)
DOW   31,591.58 (+2.13%)
QQQ   322.20 (+2.57%)
AAPL   126.10 (+3.99%)
MSFT   237.00 (+1.99%)
FB   260.76 (+1.22%)
GOOGL   2,061.59 (+1.96%)
TSLA   714.67 (+5.80%)
AMZN   3,123.30 (+0.98%)
NVDA   549.87 (+0.24%)
BABA   240.47 (+1.14%)
CGC   34.90 (+6.56%)
GE   13.28 (+5.90%)
MU   95.64 (+4.49%)
NIO   50.27 (+9.81%)
AMD   85.87 (+1.61%)
T   28.22 (+1.18%)
F   12.07 (+3.16%)
ACB   11.30 (+7.41%)
DIS   195.05 (+3.18%)
BA   224.76 (+6.01%)
NFLX   549.87 (+2.05%)
BAC   35.67 (+2.77%)
S&P 500   3,899.95 (+2.33%)
DOW   31,591.58 (+2.13%)
QQQ   322.20 (+2.57%)
AAPL   126.10 (+3.99%)
MSFT   237.00 (+1.99%)
FB   260.76 (+1.22%)
GOOGL   2,061.59 (+1.96%)
TSLA   714.67 (+5.80%)
AMZN   3,123.30 (+0.98%)
NVDA   549.87 (+0.24%)
BABA   240.47 (+1.14%)
CGC   34.90 (+6.56%)
GE   13.28 (+5.90%)
MU   95.64 (+4.49%)
NIO   50.27 (+9.81%)
AMD   85.87 (+1.61%)
T   28.22 (+1.18%)
F   12.07 (+3.16%)
ACB   11.30 (+7.41%)
DIS   195.05 (+3.18%)
BA   224.76 (+6.01%)
NFLX   549.87 (+2.05%)
BAC   35.67 (+2.77%)
S&P 500   3,899.95 (+2.33%)
DOW   31,591.58 (+2.13%)
QQQ   322.20 (+2.57%)
AAPL   126.10 (+3.99%)
MSFT   237.00 (+1.99%)
FB   260.76 (+1.22%)
GOOGL   2,061.59 (+1.96%)
TSLA   714.67 (+5.80%)
AMZN   3,123.30 (+0.98%)
NVDA   549.87 (+0.24%)
BABA   240.47 (+1.14%)
CGC   34.90 (+6.56%)
GE   13.28 (+5.90%)
MU   95.64 (+4.49%)
NIO   50.27 (+9.81%)
AMD   85.87 (+1.61%)
T   28.22 (+1.18%)
F   12.07 (+3.16%)
ACB   11.30 (+7.41%)
DIS   195.05 (+3.18%)
BA   224.76 (+6.01%)
NFLX   549.87 (+2.05%)
BAC   35.67 (+2.77%)
Log in
NASDAQ:FOLD

Amicus Therapeutics Stock Forecast, Price & News

$11.87
-0.41 (-3.34 %)
(As of 03/1/2021 11:46 AM ET)
Add
Compare
Today's Range
$11.78
Now: $11.87
$12.46
50-Day Range
$11.86
MA: $18.41
$23.29
52-Week Range
$6.25
Now: $11.87
$25.39
Volume155,542 shs
Average Volume4.40 million shs
Market Capitalization$3.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Amicus Therapeutics logo

Headlines

Newell Brands, Amicus fall; HubSpot, Cognex rise
February 12, 2021 |  marketbeat.com
Amicus Therapeutics FY 2020 top line up 43%
March 1, 2021 |  seekingalpha.com
Earnings Preview for Amicus Therapeutics
February 26, 2021 |  finance.yahoo.com
Amicus Therapeutics Becomes Oversold (FOLD)
February 12, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000
Employees584
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$182.24 million
Book Value$1.87 per share

Profitability

Net Income$-356,390,000.00
Net Margins-120.18%

Miscellaneous

Market Cap$3.09 billion
Next Earnings Date3/1/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

377th out of 1,962 stocks

Pharmaceutical Preparations Industry

190th out of 772 stocks

Analyst Opinion: 4.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$11.87
-0.41 (-3.34 %)
(As of 03/1/2021 11:46 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

Is Amicus Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Amicus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FOLD, but not buy additional shares or sell existing shares.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Amicus Therapeutics?

Wall Street analysts have given Amicus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.03. The biopharmaceutical company had revenue of $67.44 million for the quarter, compared to the consensus estimate of $65.04 million. Amicus Therapeutics had a negative net margin of 120.18% and a negative trailing twelve-month return on equity of 73.81%.
View Amicus Therapeutics' earnings history
.

How has Amicus Therapeutics' stock been impacted by COVID-19?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FOLD stock has increased by 49.9% and is now trading at $12.07.
View which stocks have been most impacted by COVID-19
.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $261-261 million, compared to the consensus revenue estimate of $259.24 million.

What price target have analysts set for FOLD?

12 brokers have issued 1-year price targets for Amicus Therapeutics' stock. Their forecasts range from $12.50 to $31.00. On average, they anticipate Amicus Therapeutics' share price to reach $20.79 in the next twelve months. This suggests a possible upside of 72.3% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • Mr. John F. Crowley, Chairman & CEO (Age 54, Pay $1.96M)
  • Mr. Bradley L. Campbell M.B.A., Pres, COO & Director (Age 45, Pay $899.2k)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 55, Pay $630.45k)
  • Dr. Hung Viet Do, Chief Scientific Officer (Age 53, Pay $637.43k)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 58, Pay $686.59k)
  • Ms. Samantha Prout, VP of Fin., Global Controller & Principal Accounting Officer (Age 43)
  • Dr. Enrique Diloné, Sr. VP of Technical Operations (Age 54)
  • Andrew Faughnan, Director of Investor Relations
  • Mr. Patrik S. Florencio, Sr. VP, Global Chief Compliance & Risk Officer
  • Ms. Diana Moore, Head of Global Corp. Communications

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.40%), Morgan Stanley (4.89%), Janus Henderson Group PLC (4.32%), Avoro Capital Advisors LLC (3.45%), Lone Pine Capital LLC (2.56%) and Northern Trust Corp (1.24%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics
.

Which major investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Avoro Capital Advisors LLC, Clearbridge Investments LLC, Victory Capital Management Inc., Dimensional Fund Advisors LP, Panagora Asset Management Inc., Peregrine Capital Management LLC, and Rothschild & Co. Asset Management US Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Lone Pine Capital LLC, Morgan Stanley, Canada Pension Plan Investment Board, BlackRock Inc., Price T Rowe Associates Inc. MD, Rice Hall James & Associates LLC, Cardan Capital Partners LLC, and Hood River Capital Management LLC.
View insider buying and selling activity for Amicus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $12.07.

How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of $3.15 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 584 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

Where are Amicus Therapeutics' headquarters?

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.